As the effect of targeting the DPP-4-GLP-1 pathway on exercise tolerance in humans with HF remains unclear, we performed this systematic review and meta-analysis to investigate whether DPP-4 inhibitors/GLP-1 RAs could improve exercise tolerance in HF patients. The gene discussed is DPP4; the disease is hydrops fetalis.